
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp is positioned favorably due to increasing physician comfort with chronic use of its lead candidate, apitegromab, which enhances expectations for meaningful improvements in patient independence and reduced caregiver burden. Positive feedback from Key Opinion Leaders (KOLs) indicates that the treatment may lead to sustained functional gains in patients with Spinal Muscular Atrophy, reinforcing confidence in the drug's efficacy and its market potential. The company's valuation methodology has been refined, reflecting optimism regarding future revenue growth, leading to an upward adjustment in price targets based on lower share counts and improved operational readiness for the product launch.
Bears say
Scholar Rock Holding reported a net loss of $91.0 million in its Q4 2025 results, which is better than consensus expectations but still reflects ongoing financial challenges. The delay in the anticipated launch of apitegromab has led to a downward revision in peak sales projections, now estimated at $1.7 billion by 2035, highlighting uncertainty in revenue potential. Additional risks include potential regulatory approval delays and competitive dynamics that could hinder market share, further contributing to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares